Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents

Back to Search
Print
Bookmark Trial

NCT00479258

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Buffalo, New York, 14222, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 1 Diabetes Mellitus
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-17 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects with Type 1 diabetes mellitus for more than 6 months.

- Males and females ages 6 to 17 years.

- Subjects should be receiving, or be able to tolerate, at a minimum a 3 unit pre prandial dose of short acting subcutaneous insulin.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects using an insulin pump


- Smoking

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Type 1 Diabetes MellitusSafety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents
NCT00479258
  1. Buffalo, New York
ALL GENDERS
6 Years+
years
MULTIPLE SITES
Type 1 Diabetes MellitusA Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes
NCT02038764
  1. San Diego, California
  2. San Diego, California
  3. San Francisco, California
  4. Aurora, Colorado
  5. New Haven, Connecticut
  6. New Haven, Connecticut
  7. New Haven, Connecticut
  8. Atlanta, Georgia
  9. Chicago, Illinois
  10. Chicago, Illinois
  11. Chicago, Illinois
  12. Chicago, Illinois
  13. Worcester, Massachusetts
  14. Worcester, Massachusetts
  15. Minneapolis, Minnesota
  16. Minneapolis, Minnesota
  17. Saint Louis, Missouri
  18. Saint Louis, Missouri
  19. Saint Louis, Missouri
  20. Durham, North Carolina
  21. Durham, North Carolina
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Type 1 Diabetes MellitusSix Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes
NCT00424333
  1. Duarte, California
  2. Long Beach, California
  3. Los Angeles, California
  4. Stanford, California
  5. Denver, Colorado
  6. New Haven, Connecticut
  7. Gainesville, Florida
  8. Hollywood, Florida
  9. Miami, Florida
  10. Tallahassee, Florida
  11. Peoria, Illinois
  12. Skokie, Illinois
  13. Lutherville, Maryland
  14. Waltham, Massachusetts
  15. Minneapolis, Minnesota
  16. Columbia, Missouri
  17. Bronx, New York
  18. New Hyde Park, New York
  19. Rochester, New York
  20. Syracuse, New York
  21. Durham, North Carolina
  22. Winston-salem, North Carolina
  23. Portland, Oregon
  24. Pittsburgh, Pennsylvania
  25. Dallas, Texas
  26. Houston, Texas
  27. Burlington, Vermont
  28. Charlottesville, Virginia
  29. Charlottsville, Virginia
  30. Seattle, Washington
  31. Edmonton, Alberta
  32. Hamilton, Ontario
  33. Mississauga, Ontario
  34. Toronto, Ontario
  35. Montreal, Quebec
ALL GENDERS
12 Years+
years
MULTIPLE SITES
Type 1 Diabetes MellitusSix Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 1 Diabetes Mellitus.
NCT00424437
  1. Burlingame, California
  2. Irvine, California
  3. Newport Beach, California
  4. San Diego, California
  5. San Francisco, California
  6. Tustin, California
  7. Hartford, Connecticut
  8. Washington, District of Columbia
  9. Atlanta, Georgia
  10. Stockbridge, Georgia
  11. Chicago, Illinois
  12. Lexington, Kentucky
  13. Columbia, Missouri
  14. St Louis, Missouri
  15. St. Louis, Missouri
  16. Omaha, Nebraska
  17. Albuquerque, New Mexico
  18. Buffalo, New York
  19. Manhasset, New York
  20. New Hyde Park, New York
  21. New York, New York
  22. Greenville, North Carolina
  23. Cleveland, Ohio
  24. Portland, Oregon
  25. Austin, Texas
  26. Dallas, Texas
  27. Irving, Texas
  28. San Antonio, Texas
  29. Charlottesville, Virginia
  30. Renton, Washington
  31. Calgary, Alberta
  32. Winnipeg, Manitoba
  33. St John's, Newfoundland and Labrador
  34. Halifax, Nova Scotia
  35. London, Ontario
  36. Toronto, Ontario
  37. Laval, Quebec
ALL GENDERS
12 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents
Official Title  ICMJE Safety And Efficacy Of Exubera® (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents Ages 6-17 Years With Type 1 Diabetes Mellitus: A 12 Month, Outpatient, Randomized, Open Label, Parallel Group Comparative Trial.
Brief Summary To assess the safety and efficacy of Exubera on pulmonary function and glycemic control in subjects ages 6-17 over a 1 year period.
Detailed Description Pfizer announced in October 2007 that it would stop marketing Exubera. At that time recruitment for the pediatric study, A2171083, was placed on hold. Two subjects completed the informed consent/assent process and entered the A2171083 study but none received treatment. The first subject withdrew consent during the Baseline Run-in period which was prior to Randomization. The second subject screen failed at Visit 1. After this time, Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, study A2171083 was terminated and no further recruitment took place.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Diabetes Mellitus, Type 1
Intervention  ICMJE
  • Drug: Inhaled insulin (Exubera)
    Inhaled insulin with dose adjusted according to premeal blood glucose
  • Drug: Subcutaneous Insulin (subject's prescribed)
    Subcutaneous insulin with dose adjusted according to premeal blood glucose
Study Arms  ICMJE
  • Experimental: Inhaled insulin (Exubera)
    Intervention: Drug: Inhaled insulin (Exubera)
  • Active Comparator: Subcutaneous Insulin (subject's prescribed)
    Intervention: Drug: Subcutaneous Insulin (subject's prescribed)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: August 31, 2018)		2
Original Enrollment  ICMJE
 (submitted: May 24, 2007)		554
Actual Study Completion Date  ICMJE October 2007
Actual Primary Completion Date October 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects with Type 1 diabetes mellitus for more than 6 months.
  • Males and females ages 6 to 17 years.
  • Subjects should be receiving, or be able to tolerate, at a minimum a 3 unit pre prandial dose of short acting subcutaneous insulin.

Exclusion Criteria:

  • Subjects using an insulin pump
  • Smoking
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 6 Years to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00479258
Other Study ID Numbers  ICMJE A2171083
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date August 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP